
|Articles|July 1, 2020
GlobalData Reports Sales for Big Pharma Companies Have Increased Due to COVID-19
Advertisement
GlobalData, a leading data and analytics company, has found that the COVID-19 pandemic has led to temporarily increased drug sales for big bio/pharma companies in the first quarter (Q1) of 2020. This increase was due to people stockpiling in preparation for limited medical access during the lockdown.
GlobalData’s Pharma Intelligence Center Drug Sales and Forecast Database reveals that global sales in Q1 2020 for companies that were not developing a COVID-19 drug saw an 8% increase in sales when compared to the archived global sales forecast for the same time period. In contrast, companies that were developing a COVID-19 drug only saw a 3% increase.
For more information, click
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
2
What Kinds of Disruption are GLP-1s Expected to Face
3
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
4
The Evolving Relationship Between FDA and Biotech
5




